+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer

Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer

European Urology 75(5): 853-860

A fast, noninvasive test with high sensitivity (SN) and a negative predictive value (NPV), which is able to detect recurrences in bladder cancer (BC) patients, is needed. A newly developed urine assay, Xpert Bladder Cancer Monitor (Xpert), measures five mRNA targets (ABL1, CRH, IGF2, UPK1B, and ANXA10) that are frequently overexpressed in BC. To validate Xpert characteristics in patients previously diagnosed with non-muscle-invasive BC. Voided precystoscopy urine samples were prospectively collected at 22 sites. Xpert, cytology, and UroVysion were performed. If cystoscopy was suspicious for BC, a histologic examination was performed. Additionally, technical validation was performed and specificity was determined in patients without a history or clinical evidence of BC. Test characteristics were calculated based on cystoscopy and histology results, and compared between Xpert, cytology, and UroVysion. Of the eligible patients, 239 with a history of BC had results for all assays. The mean age was 71 yr; 190 patients were male, 53 never smoked, and 64% had previous intravesical immunotherapy (35%) or chemotherapy (29%). Forty-three cases of recurrences occurred. Xpert had overall SN of 74% (95% confidence interval [CI]: 60-85) and 83% (95% CI: 64-93) for high-grade (HG) tumors. The NPV was 93% (95% CI: 89-96) overall and 98% (95% CI: 94-99) for HG tumors. Specificity was 80% (95% CI: 73-85). Xpert SN and NPV were superior to those of cytology and UroVysion. Specificity in non-BC individuals (n=508) was 95% (95% CI: 93-97). Xpert has an improved NPV compared with UroVysion and cytology in patients under follow-up for BC. It represents a promising tool for excluding BC in these patients, reducing the need for cystoscopy. Xpert is an easy-to-perform urine test with good performance compared with standard urine tests. It should help optimize the follow-up of recurrent bladder cancer patients.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 066010316

Download citation: RISBibTeXText

PMID: 30553612

DOI: 10.1016/j.eururo.2018.11.055

Related references

Validation of a mRNA-based urine test for bladder cancer detection in patients with hematuria. European Urology Suppl.s 16(3): E190-E191, 2017

Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance. Bju International 121(1): 29-37, 2018

Performance characteristics of a mRNA-based urine test for the detection of bladder cancer recurrence. European Urology Suppl.s 16(3): E193-E194, 2017

The diagnostic value of urine-based survivin mRNA test using reverse transcription-polymerase chain reaction for bladder cancer: a systematic review. Chinese Journal of Cancer 29(4): 441-446, 2010

Using gene expression from urine sediment to diagnose prostate cancer: development of a new multiplex mRNA urine test and validation of current biomarkers. Bmc Cancer 16: 76, 2016

Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings. American Journal of Clinical Pathology 127(2): 295-301, 2007

Methylation markers for urine-based detection of bladder cancer: the next generation of urinary markers for diagnosis and surveillance of bladder cancer. Advances in Urology 2012: 503271, 2012

Surveillance, initial assessment, and subsequent progress of patients with superficial bladder cancer in a prospective longitudinal study. National Bladder Cancer Collaborative Group A (NBCCGA). Cancer Research 37(8 Pt 2): 2907-2910, 1977

Comparison of the ImmunoCyt test and urinary cytology with other urine tests in the detection and surveillance of bladder cancer. World Journal of Urology 22(2): 145-149, 2004

Combinations of urine-based tumour markers in bladder cancer surveillance. Scandinavian Journal of Urology and Nephrology 43(6): 461-466, 2009

Urine-based biomarkers for the early detection and surveillance of non-muscle invasive bladder cancer. Minerva Urologica e Nefrologica 60(4): 217-235, 2008

Impact of bladder neck involvement on progression in patients with primary non-muscle invasive bladder cancer: a prospective validation study. Urologic Oncology 32(1): 38.E29, 2014

Validation and clinicopathologic associations of a urine-based bladder cancer biomarker signature. Diagnostic Pathology 9: 200, 2014

HTERT mRNA expression in urine as a useful diagnostic tool in bladder cancer. Comparison with cytology and NMP22 BladderCheck Test®. Actas Urologicas Espanolas 42(8): 524-530, 2018

Validation study of a noninvasive urine test for diagnosis and prognosis assessment of bladder cancer: evidence for improved models. Journal of Urology 191(1): 261-269, 2014